Last updated: March 2026
GHK-Cu + KPV + BPC-157 + TB-500 in a single pre-mixed vial. Each peptide hits a different pathway — here's how they work together and what the research behind each component actually shows.
Four research peptides, each with its own mechanism. The blend covers collagen repair, inflammation control, angiogenesis, and cell migration — the four pillars of tissue recovery.
Glycine-Histidine-Lysine complexed with copper (Cu²⁺). Found naturally in human blood plasma — 200ng/mL at age 20, declining to ~80ng/mL by age 60. Drives collagen synthesis, stimulates wound healing, activates antioxidant enzymes, and remodels the extracellular matrix. The collagen anchor of this blend.
50mg (62.5% of blend)Lys-Pro-Val — the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). Potent anti-inflammatory action via NF-κB inhibition. One of the few peptides proven to work orally — absorbed via PepT1 intestinal transporter. Reduces severity of DSS-induced colitis in mice (Gastroenterology 2008, PMC2431115). Suppresses the inflammatory cascade that would otherwise impede healing.
10mg15 amino acid gastric pentadecapeptide derived from human gastric juice proteins. Drives angiogenesis (new blood vessel formation), accelerates tendon and ligament healing, protects GI mucosa, and upregulates growth factor receptors. Also modulates dopamine and serotonin pathways. The blood-vessel builder of this blend.
10mg43 amino acid synthetic fragment of Thymosin Beta-4. Binds G-actin and promotes cell migration to injury sites, wound healing, and tissue remodeling. Reduces inflammation, promotes angiogenesis, and has been studied in cardiac repair contexts. Mobilizes stem cells to areas of damage. The cell-migration director of this blend.
10mgEach component addresses a different phase of tissue repair. The blend is designed to hit all four phases simultaneously rather than relying on a single mechanism.
KPV immediately suppresses the inflammatory cascade via NF-κB inhibition. Unchecked inflammation is the primary obstacle to healing — by knocking it down first, KPV sets the stage for the repair peptides to work effectively without inflammatory interference.
BPC-157 and TB-500 both drive angiogenesis through different pathways. New vasculature brings oxygen and nutrients to the damaged tissue — essential before structural repair can begin. Without adequate blood supply, collagen and matrix repair is inefficient.
TB-500's G-actin binding promotes directed cell migration — it helps repair cells physically move to the injury site. This is critical for tissue healing where the damage is localized: you need cells to arrive before they can rebuild.
GHK-Cu drives collagen and elastin synthesis, rebuilding the extracellular matrix. BPC-157 accelerates tendon and ligament fiber repair. Together they address structural tissue rebuilding — the final phase that restores strength and function to the healed tissue.
GHK-Cu occurs naturally in human blood plasma, but levels decline dramatically with age. This decline correlates with reduced wound healing capacity and collagen turnover in older adults.
The following is a community-sourced report from Reddit. It is anecdotal — not a clinical trial. We include it for context, clearly labeled as such.
Source: Reddit peptides community (r/Peptides) — Self-reported, not verified
49-year-old male with torn triceps tendon (surgical repair). Started KLOW blend the day after surgery. At 6-week follow-up, orthopedic surgeon reported recovery was 3 months ahead of schedule — cancelled remaining physical therapy appointments. User reported full recovery with all strength returned.
This represents a single case report with no controls, no blinding, and no confirmed peptide quality verification. Individual results vary dramatically. Surgical recovery depends on many factors including surgery quality, post-op care, physical therapy, diet, age, and baseline fitness. This anecdote does not constitute evidence of efficacy.
Protocols in use by the research community. These are not medical prescriptions — they are reference points for how the blend is currently being used.
⚠️ Research Use Only: The KLOW blend is NOT FDA-approved for human use. The individual components (GHK-Cu, KPV, BPC-157, TB-500) are research peptides. None have completed Phase 3 human clinical trials for tissue repair indications. Always consult a qualified healthcare provider before use.
Essential research supplies for peptide handling. These are general supplies — not the peptides themselves.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice. The KLOW blend and its individual components (GHK-Cu, KPV, BPC-157, TB-500) are NOT approved by the FDA for human therapeutic use. They are research compounds. The community reports included on this page are anecdotal and self-reported — they do not constitute clinical evidence. Study data cited comes from animal models and cell cultures; these findings may not translate to humans. Always consult a qualified healthcare provider before use. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.